Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
SAGE Therapeutics (SAGE)
NASDAQ:SAGE
SAGE Therapeutics (SAGE) Stock Price & Analysis
873 Followers
SAGE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.76 - $49.74
Previous Close$10.86
Volume1.02M
Average Volume (3M)1.32M
Market Cap
$653.58M
Enterprise Value-$94.44M
Total Cash (Recent Filing)$753.18M
Total Debt (Recent Filing)$5.17M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Aug 06, 2024EPS Estimate
-$1.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.40
Shares Outstanding60,182,031
10 Day Avg. Volume1,850,893
30 Day Avg. Volume1,322,600
Standard Deviation0.16
R-Squared0.09
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.82
Price to Sales (P/S)87.15
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-8.33
Enterprise Value/Gross Profit-1.09
Enterprise Value/Ebitda0.15
Forecast
1Y Price Target
$18.00Price Target Upside63.19% Upside
Rating ConsensusHold
Number of Analyst Covering19
SAGE Therapeutics News
PremiumCompany Announcements
SAGE Therapeutics Shareholders Back Governance and Incentives
Bulls Say, Bears Say
Bulls Say
Clinical TrialsManagement was encouraged by the suggestion of a potential signal on the overall HD-CAB assessment and from several sub-tests of the HD-CAB that demonstrated directional improvement in the dalzanemdor arm vs placebo -- which increased their confidence in the DIMENSION trial.
Market PotentialEarly signs suggest payer coverage seems to be relatively lenient.
Product DifferentiationZurzuvae's differentiated mechanism and faster onset of action are promising.
Bears Say
Drug Approval67% of psychiatrists expressed discomfort prescribing Zurzuvae to breastfeeding patients, indicating potential challenges in market acceptance.
Financial PerformanceAnalyst maintains an Underperform rating with a $14 price objective, reflecting a cautious outlook on the stock's future performance.
Study ResultsThe SURVEYOR study's small size and short duration limit its reliability, making it difficult to draw meaningful conclusions about dalzanemdor's effectiveness.
---
Ownership Overview
7.91% Insiders
34.18% Mutual Funds
46.70% Other Institutional Investors
11.21% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SAGE FAQ
What was SAGE Therapeutics’s price range in the past 12 months?
SAGE Therapeutics lowest stock price was $9.76 and its highest was $49.74 in the past 12 months.
What is SAGE Therapeutics’s market cap?
Currently, no data Available
When is SAGE Therapeutics’s upcoming earnings report date?
SAGE Therapeutics’s upcoming earnings report date is Aug 06, 2024 which is in 35 days.
How were SAGE Therapeutics’s earnings last quarter?
SAGE Therapeutics released its earnings results on Apr 25, 2024. The company reported -$1.8 earnings per share for the quarter, missing the consensus estimate of -$1.649 by -$0.151.
Is SAGE Therapeutics overvalued?
According to Wall Street analysts SAGE Therapeutics’s price is currently Undervalued.
Does SAGE Therapeutics pay dividends?
SAGE Therapeutics does not currently pay dividends.
What is SAGE Therapeutics’s EPS estimate?
SAGE Therapeutics’s EPS estimate is -$1.64.
How many shares outstanding does SAGE Therapeutics have?
SAGE Therapeutics has 60,182,030 shares outstanding.
What happened to SAGE Therapeutics’s price movement after its last earnings report?
SAGE Therapeutics reported an EPS of -$1.8 in its last earnings report, missing expectations of -$1.649. Following the earnings report the stock price went down -3%.
Which hedge fund is a major shareholder of SAGE Therapeutics?
Among the largest hedge funds holding SAGE Therapeutics’s share is Fisher Asset Management LLC. It holds SAGE Therapeutics’s shares valued at 8M.
---
SAGE Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$18.00 (63.19% Upside)
$18.00 (63.19% Upside)
Blogger Sentiment
Bullish
SAGE Sentiment 66%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 641.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.81%
12-Months-Change
Fundamentals
Return on Equity
-54.72%
Trailing 12-Months
Asset Growth
-37.12%
Trailing 12-Months
Company Description
SAGE Therapeutics
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
---
SAGE Company Deck
---
SAGE Earnings Call
Q1 2024
0:00 / 0:00
---
SAGE Stock 12 Month Forecast
Average Price Target
$18.00
▲(63.19% Upside)
Technical Analysis
Best Analysts Covering SAGE
1 Year
1 Year Success Rate
7/17 ratings generated profit
1 Year Average Return
-8.36%
reiterated a sell rating 21 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of -8.36% per trade.
---